SCM
NRIX icon

Sterling Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Sterling Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.3K Sell
3,376
-2,401
-42% -$39.8K ﹤0.01% 1620
2025
Q4 		$110K Buy
5,777
+575
+11% +$8.26K ﹤0.01% 1495
2025
Q3 		$48.1K Buy
5,202
+3,167
+156% +$32.9K ﹤0.01% 1763
2025
Q2 		$23.2K Buy
2,035
+1,581
+348% +$17.1K ﹤0.01% 1739
2025
Q1 		$5.39K Sell
454
-279
-38% -$4.67K ﹤0.01% 2129
2024
Q4 		$13.8K Buy
733
+624
+572% +$14.3K ﹤0.01% 2007
2024
Q3 		$2.45K Buy
+109
New +$2.47K ﹤0.01% 2092

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Sterling Capital Management's NRIX Position: Q1 2026 in Review

Sterling Capital Management reduced its Nurix Therapeutics (NRIX) stake by 42% in Q1 2026, selling an estimated $39.8K and leaving 3,376 shares worth $52.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

Sterling Capital Management first reported a position in NRIX in Q3 2024 and has held it in 7 quarters since. The position peaked at $110K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Sterling Capital Management held 3,376 shares of Nurix Therapeutics worth $52.3K as of Q1 2026.
  • Sterling Capital Management sold 2,401 Nurix Therapeutics shares in Q1 2026, an estimated $39.8K.
  • Nurix Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #1620 holding.
  • Sterling Capital Management first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Nurix Therapeutics position peaked at $110K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.